Reversing uL3-mediated chemoresistance through synergistic combination of 5-FU and G-quadruplex ligands
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf046 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Anna Di Porzio und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Fluorouracil, Drug Resistance, Neoplasm, G-Quadruplexes, Colorectal Neoplasms. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nazionale “National Center for Gene Therapy and Drugs based on RNA Technology” Codice progetto MUR.
Abstract (Originalsprache)
Chemoresistance represents a significant challenge in the chemotherapy of colorectal cancer (CRC), limiting the effectiveness. In this regard, gene expression heterogeneity plays a critical role, influencing cancer cell adaptability and survival under chemotherapy. Our previous data revealed that ribosomal protein uL3 positively correlates with both chemoresistance and poor prognosis in CRC patients. This study explores the combination of 5-fluorouracil (5-FU), the first-line treatment of CRC, with G-quadruplex (G4) ligands, which have recently emerged as promising candidates for cancer therapy, to overcome uL3-mediated chemoresistance. We found that resistant p53-deficient and uL3-silenced CRC cells showed increased levels of G4 structures compared to both sensitive p53-deficient and p53-proficient cells, thereby exhibiting vulnerability to the cytotoxic effects of two well-established G4 ligands, pyridostatin (PDS) and RHPS4. The combination of 5-FU with PDS or RHPS4 exhibited a synergistic effect, selectively targeting tumor cells. This approach enabled a >10-fold reduction in the 5-FU dose, improving treatment efficacy. The effectiveness of this combination was further validated in vivo using uL3-silenced CRC cell-derived xenografts in a chicken embryo model. Overall, our findings highlight a novel and promising combination strategy that targets chemoresistance in CRCs characterized by non-functional p53 and reduced levels of uL3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
- CEINGE-Biotecnologie Avanzate Franco Salvatore, Via Gaetano Salvatore 486 80131 Naples, Italy.
- Istituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche, Via Pietro Castellino 111, 80131 Naples, Italy.
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples,Italy.
- Department of Molecular Biology, Ruđer Bošković Institute, Bijenička 54, HR-10000 Zagreb, Croatia.
ORCID-Profile: Annalisa Pecoraro, Camilla Danisi, Isidoro Feliciello, Antonio Randazzo
Förderung
- Nazionale “National Center for Gene Therapy and Drugs based on RNA Technology” Codice progetto MUR
Zitieren
APA
Di Porzio, A., Pecoraro, A., Danisi, C., Persico, C., D'Auria, L., Germoglio, M., Iaccarino, N., Feliciello, I., Giancola, C., Randazzo, A., Russo, G., & Russo, A. (2025). Reversing uL3-mediated chemoresistance through synergistic combination of 5-FU and G-quadruplex ligands. NAR Cancer. https://doi.org/10.1093/narcan/zcaf046
Vancouver
Di Porzio A, Pecoraro A, Danisi C, Persico C, D'Auria L, Germoglio M, et al. Reversing uL3-mediated chemoresistance through synergistic combination of 5-FU and G-quadruplex ligands. NAR Cancer. 2025. doi:10.1093/narcan/zcaf046
BibTeX
@article{DiPorzio2025,
author = {Di Porzio, Anna and Pecoraro, Annalisa and Danisi, Camilla and Persico, Carolina and D'Auria, Ludovica and Germoglio, Marcello and Iaccarino, Nunzia and Feliciello, Isidoro and Giancola, Concetta and Randazzo, Antonio and Russo, Giulia and Russo, Annapina},
title = {Reversing uL3-mediated chemoresistance through synergistic combination of 5-FU and G-quadruplex ligands},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf046}
}
EUVIMED